Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 20/20 | 0.68 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982229 | 0.92 | OXTR (0.80) | OXTRAVPR2 | |
| SCHEMBL1598441 | 0.92 | OXTR (0.80) | OXTRAVPR2 | |
| SCHEMBL9975175 | 0.92 | OXTR (0.80) | OXTRAVPR2 | |
| SCHEMBL5420992 | 0.92 | OXTR (0.80) | OXTRAVPR2 | |
| SCHEMBL13824096 | 0.88 | OXTR (0.84) | OXTRAVPR2CYP3A4AVPR1A | |
| SCHEMBL13824411 | 0.83 | OXTR (0.84) | OXTRAVPR2CYP3A4AVPR1A | |
| SCHEMBL1598563 | 0.81 | OXTR (1.00) | OXTRAVPR2 | |
| SCHEMBL5423436 | 0.80 | OXTR (1.00) | OXTRAVPR2 | |
| SCHEMBL1598224 | 0.79 | OXTR (0.81) | OXTRAVPR2 | |
| SCHEMBL9975177 | 0.79 | OXTR (0.81) | OXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919492-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-20100305127-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20090247541-A1 | Novel compounds | BORTHWICK ALAN DAVID | 2009-10-01 | — | — | US | disclosed |
| US-7550462-B2 | Piperazinediones as oxytocin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247541-A1 | Novel compounds | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885CYP3A4 1843/4885 |
| US-20100305127-A1 | NOVEL COMPOUNDS | OXTR, PRMT3, PRMT1 | OXTR 1/4885AVPR2 4/4885CYP3A4 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.